SEC Filings

Form 10-Q
ZOMEDICA PHARMACEUTICALS CORP. filed this Form 10-Q on 08/09/2018
Document Outline
Entire Document (2638.4 KB)
Subdocument 1 - 10-Q - FORM 10-Q
Page 1 - UNITED STATES
Page 2 - Zomedica Pharmaceuticals Corporation
Page 3 - PART I FINANCIAL INFORMATION
Page 4 - Zomedica Pharmaceuticals Corp.
Page 5 - Zomedica Pharmaceuticals Corp.
Page 6 - Zomedica Pharmaceuticals Corp.
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - Issued and outstanding common stock:
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - Item 2. MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Page 20 - N/A
Page 21 - MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
Page 22 - Revenue
Page 23 - Critical Accounting Policies and Significant Judgments and Estimates
Page 24 - Translation of Foreign Currencies
Page 25 - Results of Operations
Page 26 - Cash Flows
Page 27 - Operating Activities
Page 28 - Liquidity and Capital Resources
Page 29 - Off Balance Sheet Arrangements
Page 30 - Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Page 31 - PART II OTHER INFORMATION
Page 32 - We are substantially dependent on the success of our lead product candidates, and cannot be certain
Page 33 - Our product candidates will face significant competition and may be unable to compete effectively.
Page 34 - Development of product candidates for use in companion animal health is an inherently expensive, tim
Page 35 - We will rely on third parties to conduct certain portions of our development activities. If these th
Page 36 - Risks Related to Intellectual Property
Page 37 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Page 38 - SIGNATURES
Page 39 - EXHIBIT INDEX
Subdocument 2 - EX-10.24 - EXHIBIT 10.24
Page 1 - Exhibit 10.24
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 7 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 8 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 9 - 2. License.
Page 10 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 11 - N/A
Page 12 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 13 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 14 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 15 - N/A
Page 16 - N/A
Page 17 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 18 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 19 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 20 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 21 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - 8. Confidential Treatment.
Page 26 - N/A
Page 27 - 10. Injunctive Relief.
Page 28 - 11. Term and Termination.
Page 29 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 30 - 12. Indemnification.
Page 31 - 16. Binding Effect.
Page 32 - N/A
Page 33 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 34 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 35 - EXHIBIT C
Page 36 - EXHIBIT D
Page 37 - Registration Period ). Subject to any comments from the staff of the Commission, such Registration S
Page 38 - Black-Out Period. Except for any Black-Out Period arising pursuant to clause (i) above, no Black-Out
Page 39 - EXHIBIT
Page 40 - EXHIBIT
Page 41 - Seraph Indemnified Parties ), against any Damages (defined below), and Zomedica will promptly reimbu
Page 42 - EXHIBIT
Page 43 - EXHIBIT
Page 44 - Plan of Distribution
Page 45 - EXHIBIT
Page 46 - EXHIBIT
Page 47 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Page 48 - [*Confidential Treatment has been requested as to certain portions of this document. Each such porti
Subdocument 3 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer